Comparative Pharmacology
Head-to-head clinical analysis: CYTADREN versus TESLAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTADREN versus TESLAC.
CYTADREN vs TESLAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglutethimide inhibits the conversion of cholesterol to pregnenolone, thereby blocking adrenal steroidogenesis. It also inhibits aromatase, reducing estrogen synthesis.
Androgen receptor inhibitor; suppresses gonadotropin secretion and reduces testosterone levels.
200 mg orally once daily
250 mg intramuscularly three times per week
None Documented
None Documented
Terminal elimination half-life: 3–4 hours in adults with normal renal function; prolonged to 8–12 hours in end-stage renal disease.
Terminal half-life approximately 2-4 hours; clinical significance: requires multiple daily dosing for steady-state maintenance.
Renal: ~60% as unchanged drug; biliary/fecal: ~25% as metabolites; minor via respiration.
Renal (primarily as metabolites) and biliary/fecal. The drug is extensively metabolized; less than 5% is excreted unchanged in urine.
Category C
Category C
Aromatase Inhibitor
Aromatase Inhibitor